Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.

Publication ,  Journal Article
Kaddurah-Daouk, R; Weinshilboum, RM; Pharmacometabolomics Research Network,
Published in: Clin Pharmacol Ther
February 2014

Metabolomics, the study of metabolism at an "omic" level, has the potential to transform our understanding of mechanisms of drug action and the molecular basis for variation in drug response. It is now possible to define metabolic signatures of drug exposure that can identify pathways involved in both drug efficacy and adverse drug reactions. In addition, the "metabotype," the metabolic "signature" of a patient, is a unique identity that contains information about drug response and disease heterogeneity. The application of metabolomics for the study of drug effects and variation in drug response is creating "pharmacometabolomics," a discipline that will contribute to personalized drug therapy and will complement pharmacogenomics by capturing environmental and microbiome-level influences on response to drug therapy. This field has the potential to transform pharmacology and clinical pharmacology in significant ways and will contribute to efforts for personalized therapy. This overview highlights developments in the new discipline of pharmacometabolomics.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Pharmacol Ther

DOI

EISSN

1532-6535

Publication Date

February 2014

Volume

95

Issue

2

Start / End Page

154 / 167

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Systems Biology
  • Selective Serotonin Reuptake Inhibitors
  • Schizophrenia
  • Pharmacology, Clinical
  • Pharmacology & Pharmacy
  • Pharmacokinetics
  • Microbiota
  • Metabolomics
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kaddurah-Daouk, R., Weinshilboum, R. M., & Pharmacometabolomics Research Network, . (2014). Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther, 95(2), 154–167. https://doi.org/10.1038/clpt.2013.217
Kaddurah-Daouk, R., R. M. Weinshilboum, and R. M. Pharmacometabolomics Research Network. “Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.Clin Pharmacol Ther 95, no. 2 (February 2014): 154–67. https://doi.org/10.1038/clpt.2013.217.
Kaddurah-Daouk R, Weinshilboum RM, Pharmacometabolomics Research Network. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther. 2014 Feb;95(2):154–67.
Kaddurah-Daouk, R., et al. “Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.Clin Pharmacol Ther, vol. 95, no. 2, Feb. 2014, pp. 154–67. Pubmed, doi:10.1038/clpt.2013.217.
Kaddurah-Daouk R, Weinshilboum RM, Pharmacometabolomics Research Network. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther. 2014 Feb;95(2):154–167.
Journal cover image

Published In

Clin Pharmacol Ther

DOI

EISSN

1532-6535

Publication Date

February 2014

Volume

95

Issue

2

Start / End Page

154 / 167

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Systems Biology
  • Selective Serotonin Reuptake Inhibitors
  • Schizophrenia
  • Pharmacology, Clinical
  • Pharmacology & Pharmacy
  • Pharmacokinetics
  • Microbiota
  • Metabolomics
  • Humans